8,792 Shares in DaVita Inc. $DVA Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC bought a new stake in shares of DaVita Inc. (NYSE:DVA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 8,792 shares of the company’s stock, valued at approximately $1,956,000.

Other hedge funds have also bought and sold shares of the company. Root Financial Partners LLC increased its position in DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after buying an additional 105 shares in the last quarter. Caitlin John LLC purchased a new position in shares of DaVita during the 4th quarter valued at about $34,000. Sankala Group LLC bought a new position in shares of DaVita during the 4th quarter valued at approximately $39,000. Canada Pension Plan Investment Board purchased a new stake in DaVita in the 2nd quarter worth approximately $43,000. Finally, Kestra Advisory Services LLC purchased a new stake in DaVita in the 4th quarter worth approximately $45,000. Institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

DVA has been the topic of several analyst reports. UBS Group lifted their price target on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. TD Cowen upgraded shares of DaVita from a “hold” rating to a “buy” rating and raised their price objective for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Truist Financial decreased their price target on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus target price of $221.75.

DaVita Price Performance

Shares of DVA opened at $180.34 on Thursday. The firm has a market cap of $11.51 billion, a P/E ratio of 14.76, a price-to-earnings-growth ratio of 0.59 and a beta of 0.88. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49. The company has a 50 day simple moving average of $213.07 and a two-hundred day simple moving average of $182.80.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.